$1.75
4.89% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US03836J1025
Symbol
APRE

Aprea Therapeutics Inc Stock price

$1.75
+0.28 19.05% 1M
-1.26 41.86% 6M
-1.54 46.81% YTD
-3.53 66.86% 1Y
-11.43 86.72% 3Y
-652.05 99.73% 5Y
-408.25 99.57% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.09 4.89%
ISIN
US03836J1025
Symbol
APRE
Sector
Industry

Key metrics

Market capitalization $9.68m
Enterprise Value $-8.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.64
EV/Sales (TTM) EV/Sales -6.48
P/S ratio (TTM) P/S ratio 7.56
P/B ratio (TTM) P/B ratio 0.62
Revenue growth (TTM) Revenue growth 33.27%
Revenue (TTM) Revenue $1.28m
EBIT (operating result TTM) EBIT $-15.26m
Free Cash Flow (TTM) Free Cash Flow $-13.00m
Cash position $19.28m
EPS (TTM) EPS $-2.36
P/E forward negative
P/S forward 59.75
EV/Sales forward negative
Short interest 1.23%
Show more

Is Aprea Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Aprea Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Aprea Therapeutics Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Aprea Therapeutics Inc forecast:

Buy
100%

Financial data from Aprea Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.28 1.28
33% 33%
100%
- Direct Costs 0.02 0.02
-
2%
1.26 1.26
-
98%
- Selling and Administrative Expenses 6.25 6.25
10% 10%
488%
- Research and Development Expense 10 10
29% 29%
801%
-15 -15
9% 9%
-1,190%
- Depreciation and Amortization 0.02 0.02
100% 100%
2%
EBIT (Operating Income) EBIT -15 -15
9% 9%
-1,192%
Net Profit -14 -14
11% 11%
-1,100%

In millions USD.

Don't miss a Thing! We will send you all news about Aprea Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aprea Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial
Neutral
GlobeNewsWire
about 2 months ago
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition
Neutral
GlobeNewsWire
about 2 months ago
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa....
More Aprea Therapeutics Inc News

Company Profile

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.

Head office United States
CEO Oren Gilad
Employees 8
Founded 2002
Website www.aprea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today